Perspective Therapeutics’ (CATX) “Outperform” Rating Reiterated at Oppenheimer

Oppenheimer reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a report released on Friday morning, Benzinga reports. Oppenheimer currently has a $22.00 price objective on the stock.

Several other brokerages have also commented on CATX. Cantor Fitzgerald reiterated an overweight rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Bank of America initiated coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They set a buy rating and a $24.00 price target on the stock. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They set a buy rating and a $21.00 price target on the stock. Royal Bank of Canada cut their price target on shares of Perspective Therapeutics from $29.00 to $27.00 and set an outperform rating on the stock in a research note on Friday, August 16th. Finally, Wedbush assumed coverage on shares of Perspective Therapeutics in a research report on Tuesday, October 1st. They set an outperform rating and a $25.00 price objective on the stock. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of Buy and an average price target of $21.43.

Perspective Therapeutics Trading Down 4.5 %

Shares of CATX opened at $12.66 on Friday. Perspective Therapeutics has a twelve month low of $2.20 and a twelve month high of $19.05. The firm has a fifty day moving average price of $13.82.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. Equities analysts expect that Perspective Therapeutics will post -0.87 EPS for the current year.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. WealthPLAN Partners LLC purchased a new stake in shares of Perspective Therapeutics in the second quarter valued at about $1,695,000. Bank of New York Mellon Corp boosted its holdings in shares of Perspective Therapeutics by 214.0% in the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock valued at $1,369,000 after acquiring an additional 93,548 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Perspective Therapeutics in the second quarter valued at about $841,000. Ally Bridge Group NY LLC purchased a new stake in shares of Perspective Therapeutics in the second quarter valued at about $3,951,000. Finally, Rhumbline Advisers purchased a new stake in Perspective Therapeutics during the second quarter worth about $630,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.